These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 31056427)

  • 21. Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials.
    Li X; Liu Y; Wang M; Gao L; Liu J; Zhang H; Wu M; Chen H; Lou J; Wang J; Chen J; Geng G; Ma Z; Ding Y
    Lancet Infect Dis; 2024 Jun; 24(6):650-664. PubMed ID: 38359854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
    Blum CA; Nigro N; Briel M; Schuetz P; Ullmer E; Suter-Widmer I; Winzeler B; Bingisser R; Elsaesser H; Drozdov D; Arici B; Urwyler SA; Refardt J; Tarr P; Wirz S; Thomann R; Baumgartner C; Duplain H; Burki D; Zimmerli W; Rodondi N; Mueller B; Christ-Crain M
    Lancet; 2015 Apr; 385(9977):1511-8. PubMed ID: 25608756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.
    Zhong NS; Sun T; Zhuo C; D'Souza G; Lee SH; Lan NH; Chiang CH; Wilson D; Sun F; Iaconis J; Melnick D
    Lancet Infect Dis; 2015 Feb; 15(2):161-71. PubMed ID: 25539586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
    Kokai-Kun JF; Roberts T; Coughlin O; Le C; Whalen H; Stevenson R; Wacher VJ; Sliman J
    Lancet Infect Dis; 2019 May; 19(5):487-496. PubMed ID: 30885591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.
    Zakrzewska JM; Palmer J; Morisset V; Giblin GM; Obermann M; Ettlin DA; Cruccu G; Bendtsen L; Estacion M; Derjean D; Waxman SG; Layton G; Gunn K; Tate S;
    Lancet Neurol; 2017 Apr; 16(4):291-300. PubMed ID: 28216232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
    Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.
    Thwaites GE; Scarborough M; Szubert A; Nsutebu E; Tilley R; Greig J; Wyllie SA; Wilson P; Auckland C; Cairns J; Ward D; Lal P; Guleri A; Jenkins N; Sutton J; Wiselka M; Armando GR; Graham C; Chadwick PR; Barlow G; Gordon NC; Young B; Meisner S; McWhinney P; Price DA; Harvey D; Nayar D; Jeyaratnam D; Planche T; Minton J; Hudson F; Hopkins S; Williams J; Török ME; Llewelyn MJ; Edgeworth JD; Walker AS;
    Lancet; 2018 Feb; 391(10121):668-678. PubMed ID: 29249276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Burns DK; Alexander RC; Welsh-Bohmer KA; Culp M; Chiang C; O'Neil J; Evans RM; Harrigan P; Plassman BL; Burke JR; Wu J; Lutz MW; Haneline S; Schwarz AJ; Schneider LS; Yaffe K; Saunders AM; Ratti E;
    Lancet Neurol; 2021 Jul; 20(7):537-547. PubMed ID: 34146512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial.
    Meijvis SC; Hardeman H; Remmelts HH; Heijligenberg R; Rijkers GT; van Velzen-Blad H; Voorn GP; van de Garde EM; Endeman H; Grutters JC; Bos WJ; Biesma DH
    Lancet; 2011 Jun; 377(9782):2023-30. PubMed ID: 21636122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
    Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
    Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.
    Boxer AL; Qureshi I; Ahlijanian M; Grundman M; Golbe LI; Litvan I; Honig LS; Tuite P; McFarland NR; O'Suilleabhain P; Xie T; Tirucherai GS; Bechtold C; Bordelon Y; Geldmacher DS; Grossman M; Isaacson S; Zesiewicz T; Olsson T; Muralidharan KK; Graham DL; O'Gorman J; Haeberlein SB; Dam T
    Lancet Neurol; 2019 Jun; 18(6):549-558. PubMed ID: 31122495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Craig TJ; Reshef A; Li HH; Jacobs JS; Bernstein JA; Farkas H; Yang WH; Stroes ESG; Ohsawa I; Tachdjian R; Manning ME; Lumry WR; Saguer IM; Aygören-Pürsün E; Ritchie B; Sussman GL; Anderson J; Kawahata K; Suzuki Y; Staubach P; Treudler R; Feuersenger H; Glassman F; Jacobs I; Magerl M
    Lancet; 2023 Apr; 401(10382):1079-1090. PubMed ID: 36868261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Gouni-Berthold I; Alexander VJ; Yang Q; Hurh E; Steinhagen-Thiessen E; Moriarty PM; Hughes SG; Gaudet D; Hegele RA; O'Dea LSL; Stroes ESG; Tsimikas S; Witztum JL;
    Lancet Diabetes Endocrinol; 2021 May; 9(5):264-275. PubMed ID: 33798466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
    Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
    Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
    Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.
    Sivapalasingam S; Kamal M; Slim R; Hosain R; Shao W; Stoltz R; Yen J; Pologe LG; Cao Y; Partridge M; Sumner G; Lipsich L
    Lancet Infect Dis; 2018 Aug; 18(8):884-893. PubMed ID: 29929783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.